Last updated: 11/07/2018 12:07:00
PGx and Susceptibility analysis for paediatric cohort of NAI113678; Safety and Tolerability of Intravenous Zanamivir in Treatment of Hospitalized Children infected with influenza virus
GSK study ID
201278
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: PGx and Susceptibility analysis for paediatric cohort of NAI113678; Safety and Tolerability of Intravenous Zanamivir in Treatment of Hospitalized Children infected with influenza virus
Trial description: PGx and Susceptibility analysis for paediatric cohort of NAI113678; Safety and Tolerability of Intravenous Zanamivir in Treatment of Hospitalized Children infected with influenza virus
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Bradley JS, Blumer JL, Romero JR, Michaels MG, Munoz FM, Kimberlin DW, Pahud B, DeBiasi RL, Yamamoto G, Roberts G, Hossain M, Shortino D, Yates PJ, Adams B, Peppercorn A. Intravenous zanamivir in hospitalized pediatric patients with influenza: an open-label study. Pediatrics. 2017;140(5).
Medical condition
Infections, Respiratory Tract
Product
zanamivir
Collaborators
Not applicable
Study date(s)
March 2012 to January 2017
Type
Not applicable
Phase
Not applicable
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
No study documents available.
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
2017-31-01
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website